PT - JOURNAL ARTICLE AU - Giuliana Scarpati AU - Daniela Baldassarre AU - Graziella Lacava AU - Filomena Oliva AU - Gabriele Pascale AU - Massimo Boffardi AU - Pasquale Pagliano AU - Vincenzo Calabrese AU - Giovanni L. Tripepi AU - Ornella Piazza TI - Krebs von den Lungen 6 levels in COVID-19 ICU Patients are Associated with Mortality AID - 10.1101/2021.11.17.21266464 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.17.21266464 4099 - http://medrxiv.org/content/early/2021/11/21/2021.11.17.21266464.short 4100 - http://medrxiv.org/content/early/2021/11/21/2021.11.17.21266464.full AB - Rationale Krebs von den Lungen 6 (KL-6) is a high molecular weight mucin-like glycoprotein produced by type II pneumocytes and bronchial epithelial cells. Elevated circulating levels of KL-6 may denote disorder of the alveolar epithelial lining.Objective Aim of this study was to verify if KL-6 values may help to risk stratify and triage severe COVID-19 patients.Methods We performed a retrospective prognostic study on 110 COVID-19 ICU patients, evaluating the predictive role of KL-6 for mortality.Measurements and Main Results The study sample was divided in two groups related according to the median KL-6 value [Group A (KL-6 lower than the log-transformed median (6.73)) and Group B (KL-6 higher than the log-transformed median)]. In both linear and logistic multivariate analyses, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (P/F) was significantly and inversely related to KL-6. Death rate was higher in group B than in group A (80.3 versus 45.9%) (p<0.001), Accordingly, the Cox regression analysis showed a significant prognostic role of KL-6 on mortality in the whole sample as well as in the subgroup with SOFA lower than its median value.Conclusions At ICU admission, KL-6 serum level was significantly lower in the survivors group. Our findings shown that, in severe COVID19 patients, elevated KL-6 was strongly associated with mortality in ICU.Competing Interest StatementThe authors have declared no competing interest.Funding StatementOP received institutional funding from Salerno Universirty (FARB 2019)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Campania SUD Institutional Review Board approved this study (protocol ID 0008402010) as minimal risk researchI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors